Cargando…

Ischemic preconditioning: Protection against myocardial necrosis and apoptosis

The phenomenon of ischemic preconditioning has been recognized as one of the most potent mechanisms to protect against myocardial ischemic injury. In experimental animals and humans, a brief period of ischemia has been shown to protect the heart from more prolonged episodes of ischemia, reducing inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Iliodromitis, Efstathios K, Lazou, Antigone, Kremastinos, Dimitrios Th
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291307/
https://www.ncbi.nlm.nih.gov/pubmed/18078014
_version_ 1782152441644449792
author Iliodromitis, Efstathios K
Lazou, Antigone
Kremastinos, Dimitrios Th
author_facet Iliodromitis, Efstathios K
Lazou, Antigone
Kremastinos, Dimitrios Th
author_sort Iliodromitis, Efstathios K
collection PubMed
description The phenomenon of ischemic preconditioning has been recognized as one of the most potent mechanisms to protect against myocardial ischemic injury. In experimental animals and humans, a brief period of ischemia has been shown to protect the heart from more prolonged episodes of ischemia, reducing infarct size, attenuating the incidence, and severity of reperfusion-induced arrhythmias, and preventing endothelial cell dysfunction. Although the exact mechanism of ischemic preconditioning remains obscure, several reports indicate that this phenomenon may be a form of receptor-mediated cardiac protection and that the underlying intracellular signal transduction pathways involve activation of a number of protein kinases, including protein kinase C, and mitochondrial K(ATP) channels. Apoptosis, a genetically programmed form of cell death, has been associated with cardiomyocyte cell loss in a variety of cardiac pathologies, including cardiac failure and those related to ischemia/reperfusion injury. While ischemic preconditioning significantly reduces DNA fragmentation and apoptotic myocyte death associated with ischemia-reperfusion, the potential mechanisms underlying this effect have not been fully clarified. A comprehensive understanding of these mechanisms and application to clinical scenarios will provide new directions in research and translate this information into new treatment approaches for reducing the extent of ischemia/reperfusion injury.
format Text
id pubmed-2291307
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-22913072008-04-22 Ischemic preconditioning: Protection against myocardial necrosis and apoptosis Iliodromitis, Efstathios K Lazou, Antigone Kremastinos, Dimitrios Th Vasc Health Risk Manag Review The phenomenon of ischemic preconditioning has been recognized as one of the most potent mechanisms to protect against myocardial ischemic injury. In experimental animals and humans, a brief period of ischemia has been shown to protect the heart from more prolonged episodes of ischemia, reducing infarct size, attenuating the incidence, and severity of reperfusion-induced arrhythmias, and preventing endothelial cell dysfunction. Although the exact mechanism of ischemic preconditioning remains obscure, several reports indicate that this phenomenon may be a form of receptor-mediated cardiac protection and that the underlying intracellular signal transduction pathways involve activation of a number of protein kinases, including protein kinase C, and mitochondrial K(ATP) channels. Apoptosis, a genetically programmed form of cell death, has been associated with cardiomyocyte cell loss in a variety of cardiac pathologies, including cardiac failure and those related to ischemia/reperfusion injury. While ischemic preconditioning significantly reduces DNA fragmentation and apoptotic myocyte death associated with ischemia-reperfusion, the potential mechanisms underlying this effect have not been fully clarified. A comprehensive understanding of these mechanisms and application to clinical scenarios will provide new directions in research and translate this information into new treatment approaches for reducing the extent of ischemia/reperfusion injury. Dove Medical Press 2007-10 /pmc/articles/PMC2291307/ /pubmed/18078014 Text en © 2007 Iliodromitis et al, publisher and licensee Dove Medical Press Ltd.
spellingShingle Review
Iliodromitis, Efstathios K
Lazou, Antigone
Kremastinos, Dimitrios Th
Ischemic preconditioning: Protection against myocardial necrosis and apoptosis
title Ischemic preconditioning: Protection against myocardial necrosis and apoptosis
title_full Ischemic preconditioning: Protection against myocardial necrosis and apoptosis
title_fullStr Ischemic preconditioning: Protection against myocardial necrosis and apoptosis
title_full_unstemmed Ischemic preconditioning: Protection against myocardial necrosis and apoptosis
title_short Ischemic preconditioning: Protection against myocardial necrosis and apoptosis
title_sort ischemic preconditioning: protection against myocardial necrosis and apoptosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291307/
https://www.ncbi.nlm.nih.gov/pubmed/18078014
work_keys_str_mv AT iliodromitisefstathiosk ischemicpreconditioningprotectionagainstmyocardialnecrosisandapoptosis
AT lazouantigone ischemicpreconditioningprotectionagainstmyocardialnecrosisandapoptosis
AT kremastinosdimitriosth ischemicpreconditioningprotectionagainstmyocardialnecrosisandapoptosis